CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its third quarter 2011 and recent business activities.
Third Quarter 2011 and Recent Highlights
Linaclotide
•At the end of September, Ironwood’s European partner, Almirall, S.A., submitted a Market Authorization Application (MAA) for linaclotide to the European Medicines Agency (EMA) for the treatment of irritable bowel syndrome with constipation (IBS-C).
Third Quarter 2011 and Recent Highlights
Linaclotide
•At the end of September, Ironwood’s European partner, Almirall, S.A., submitted a Market Authorization Application (MAA) for linaclotide to the European Medicines Agency (EMA) for the treatment of irritable bowel syndrome with constipation (IBS-C).
